In 2014 CAR-T therapy received Breakthrough Drug designation from the US Food and Drug Administration for relapsed and/or refractory acute lymphoblastic leukaemia.
In 2014 CAR-T therapy received Breakthrough Drug designation from the US Food and Drug Administration for relapsed and/or refractory acute lymphoblastic leukaemia.